How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Syphilis Assay Kit Market
- By Assay Type: Enzyme Immunoassay (EIA), Rapid Plasma Reagin (RPR) Test, Treponemal Pallidum Particle Agglutination (TPPA) Test, Fluorescent Treponemal Antibody Absorption (FTA-ABS) Test, Chemiluminescence Immunoassay (CLIA)
- By Sample Type: Serum, Plasma, Whole Blood, Cerebrospinal Fluid (CSF)
- By End User: Hospitals, Diagnostic Laboratories, Sexual Health Clinics, Blood Banks, Research Laboratories
- By Product Format: Kits, Reagents, Instruments
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Enzyme Immunoassay (EIA) leads By Assay Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Syphilis Assay Kit Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Assay Type 5
Sample Type 4
End User 5
Product Format 3
Companies profiled
Abbott Laboratories
Siemens Healthineers
bioMérieux
Fujirebio
Sekisui Diagnostics
Ortho Clinical Diagnostics
Thermo Fisher Scientific
Bio-Rad Laboratories
Alere (now part of Abbott)
Quidel Corporation
Luminex Corporation
DiaSorin
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →bioMérieux
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Fujirebio
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sekisui Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Ortho Clinical Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Thermo Fisher Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Alere (now part of Abbott)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Quidel Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Luminex Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →DiaSorin
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Becton Dickinson
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Hologic
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →GenWay Biotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$772.9M by 2033 · 7.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Enzyme Immunoassay (EIA)39.6
- Rapid Plasma Reagin (RPR) Test11.7
- Treponemal Pallidum Particle Agglutination (TPPA) Test20.2
- Fluorescent Treponemal Antibody Absorption (FTA-ABS) Test18.5
- Chemiluminescence Immunoassay (CLIA)10.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$143.3M → $249.9M · 7.2%
Europe$99.9M → $164.9M · 6.5%
Asia Pacific$91.2M → $144.5M · 5.9%
Latin America$56.4M → $105.2M · 8.1%
Middle East and Africa$43.4M → $84.4M · 8.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.422026
7.442027
7.452028
7.462029
7.472030
7.482031
7.502032
7.512033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories14.5
- Siemens Healthineers28.6
- bioMérieux5.6
- Fujirebio10.5
- Sekisui Diagnostics8.0
- Ortho Clinical Diagnostics4.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Assay Type22.6%
Sample Type15.8%
End User33.6%
Product Format28.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.4
- Europe22.0
- Asia Pacific19.3
- Latin America14.0
- Middle East and Africa11.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 76 | 84 | 86 | 80 | 96 | 81 | 84 |
| Siemens Healthineers | 68 | 69 | 77 | 81 | 91 | 82 | 78 |
| bioMérieux | 82 | 72 | 81 | 86 | 67 | 68 | 76 |
| Fujirebio | 82 | 75 | 80 | 59 | 69 | 69 | 72 |
| Sekisui Diagnostics | 72 | 66 | 65 | 68 | 70 | 62 | 67 |
| Ortho Clinical Diagnostics | 47 | 56 | 62 | 56 | 68 | 51 | 57 |
| Thermo Fisher Scientific | 54 | 54 | 51 | 45 | 46 | 54 | 51 |
| Bio-Rad Laboratories | 41 | 55 | 45 | 46 | 38 | 51 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Siemens Healthineers
- bioMérieux
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Siemens Healthineers | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| bioMérieux | ◐ | − | ◐ | ✓ | − | ✓ |
| Fujirebio | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Sekisui Diagnostics | ◐ | ◐ | ✓ | − | ◐ | − |
| Ortho Clinical Diagnostics | − | − | − | − | ◐ | ◐ |
| Thermo Fisher Scientific | − | − | − | − | ◐ | − |
| Bio-Rad Laboratories | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories84
2Siemens Healthineers78
3bioMérieux76
4Fujirebio72
5Sekisui Diagnostics67
6Ortho Clinical Diagnostics57
7Thermo Fisher Scientific51
8Bio-Rad Laboratories46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesSiemens Healthineers
Challenger3
Strong scale, closing on the leaders.
bioMérieuxFujirebioSekisui Diagnostics
Contender1
Focused players with pockets of strength.
Ortho Clinical Diagnostics
Niche2
Specialists in a single segment or region.
Thermo Fisher ScientificBio-Rad Laboratories
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Assay Type in North America, then scale across Syphilis Assay Kit Market — a $618M beachhead inside a $9.32B market.
Beachhead (SOM)$618Mobtainable near-term
Serviceable (SAM)$3.87Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Enzyme Immunoassay (EIA)
Best fit — highest urgency & budget in Assay Type.
Economic buyer81 fit
Rapid Plasma Reagin (RPR) Test
Strong fit — clear ROI and a fast path to value.
End user70 fit
Treponemal Pallidum Particle Agglutination (TPPA) Test
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Assay Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sample Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Assay Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Syphilis Assay Kit Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified22%
Evaluation15%
Closed-won6%
$19.0KCAC
$113KLTV
6.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Syphilis Assay Kit Market is a resilient opportunity — $1.00B by 2033, compounding at 5.2%.
TAM · 2025$672Mtoday
TAM · 2033$1.00Bforecast
CAGR5.2%2027–2033
Cumulative$7.45Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.00BTotal addressable market
SAM$411MServiceable available market
SOM$76MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.2% CAGR
Demand compounds through 2033, outpacing GDP across Assay Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Assay Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.00BLarge & growingTAM by 2033 at 5.2% CAGR
$411MServiceable nowreachable with today’s model
$76MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$783MBear3.4% CAGR
$1.00BBase5.2% CAGR
$1.29BBull6.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sample Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Syphilis Assay Kit Market — a $4.98B market by 2033. Plan: grow share from 8.8% to 13.7%.
Market size · 2033$4.98Btotal addressable
Market CAGR5.5%2027–2033
Target share13.7%from 8.8% today
Revenue ambition$682Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 13.7% | At risk |
| Revenue | $440M | $682M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 29.9% | 45.2% | At risk |
| Customer retention | 89.2% | 93.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Assay Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Sample Type capability
A defensible second engine — invest in Sample Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Assay Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sample Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $96M capacity & capability investment
- Greenlight bolt-on M&A in Sample Type
- Authorise North America expansion plan
- Fund R&D program for Assay Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Syphilis Assay Kit Market conversation — a $6.43B market you can size, segment and defend in minutes.
Market size · 2033$6.43Btotal opportunity
Growth4.6%CAGR to 2033
Addressable buyers1,601+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Assay Type
Goal Grow share in Assay Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 3 mopayback period
$88K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Abbott LaboratoriesSiemens HealthineersbioMérieuxFujirebioSekisui DiagnosticsOrtho Clinical DiagnosticsThermo Fisher ScientificBio-Rad Laboratories+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Syphilis Assay Kit Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Syphilis Assay Kit Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Synthetic Vitamin Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportSynthetic Viral Controls Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportSynthetic Vinyl Gloves Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportSynthetic Vascular Prostheses Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportSynthetic Vascular Patch Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportSynthetic Vascular Grafts Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportSynthetic Surgical Sutures Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportSynthetic Surgical Sealants and Adhesives Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportSynthetic Surgical Glue Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportSynthetic Surgical Glove Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportSynthetic Surgery Adhesion Barrier Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportSynthetic Small Molecule API Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.